Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Scott Nelson Live

Scott Nelson Live artwork

Who You Raise From Matters Most: Interview with Firefly Neuroscience CEO Greg Lipschitz

Jul 29, 202543 minAudio
ShareXLinkedInFacebookWhatsAppEmail

In this episode, we sat down with Greg Lipschitz (https://www.linkedin.com/in/greg-lipschitz-cfa-8a12b020/), CEO of Firefly Neuroscience (https://fireflyneuro.com/). Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology objectively...

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

[upbeat music] For us, it's not just the amount of capital that you raise, but it's also who your investors are and, and the terms that you raise them on. I see a lot of companies struggle in this aspect where they might not have the right investors long term, that as the company keeps growing and maturing, they may not be there to support that next level of growth, and then the founder's constantly out there spending all their time raising capital and not actually on, on the underlying business.

Welcome to MedSider, where you can learn from the brightest founders and CEOs in medical devices and health technology. Join tens of thousands of ambitious doers as we unpack the insights, tactics, and secrets behind the most successful life science startups in the world. Now, here's your host, Scott Nelson. Hey everyone, it's Scott in this episode of MedSider. I sat down with Greg Lipshitz, who has served as Firefly Neuroscience's CEO since March of this year, having previously been a board director for the company since December of 2022.

He brings extensive experience in private equity, investment banking, capital markets, and finance to his leadership role. As managing director of Oldstone Advisors and former VP at Laser Capital, Greg has advised on over one billion dollars in transactions throughout his career. He is a chartered financial analyst by training. Here are a few of the key things that we discussed in this conversation. First, prioritize investor quality over funding speed, even when capital is desperately needed. The wrong investors can create long-term problems that outweigh short-term cash flow relief, forcing founders into the undesirable position of constantly fundraising instead of building their businesses.

And if traditional funding routes don't fit, explore alternatives like strategic M&As or public markets that align with your business model and timeline. Second, for platform companies with broad potential, let market signals guide expansion decisions instead of trying to capture every possible use case immediately. Firefly chose dementia care as their beachhead despite having data across 12 different cognitive disorders, focusing on the aging baby boomer demographic rather than spreading itself too thin across all potential applications at once. Third, once early adopters are in place, leverage direct sales and customer feedback to drive sustainable growth.

Direct sales teams enable closer partnerships with existing users whose insights drive product improvements that accelerate future adoption. Firefly's approach of working intensively with 60 clinics to refine their offering creates a snowball effect, where clinical success, published evidence, and customer testimonials combine to reduce sales cycles for new prospects. All right, before we dive into this episode, I'm pumped to share that volume seven of MedSider Mentors is now live. This latest edition highlights key takeaways from recent MedSider interviews with incredible entrepreneurs like Bill Hunter, CEO of Canary Medical, Brian Lord, CEO of Pristine Surgical, Don Crawford, co-founder of Saphion and current CEO of Corvista Health, and other proven med tech founders and CEOs.

Look, we get it. Keeping up with every MedSider interview isn't easy. That's why we created MedSider Mentors. These e-book volumes distill the best practices and insider secrets from top founders and CEOs, all in a downloadable, easy-to-digest format. To check the latest volume out, head over to medsiderradio.com/mentors. Premium members get free access to all past and future volumes, plus a treasure trove of other resources. If you're not a premium member yet, you should definitely consider signing up. We recently revamped MedSider with swanky new features, especially for our premium members. In addition to every volume of MedSider Mentors, you'll get full access to our entire interview library dating back to 2010.

You'll also get MedSider playbooks, curated guides packed with actionable insights on topics like fundraising, regulatory challenges, reimbursement strategies, and more. And if you're fundraising, don't miss our exclusive investor database featuring over 750 life science VCs, family offices, and angels. We've even created three custom packages to help you with your next fundraise. Learn more about MedSider Mentors and our premium memberships by visiting medsiderradio.com/mentors. All right, without further ado, let's dive into the interview. [upbeat music] All right, Greg, welcome to MedSider Radio. Appreciate you coming on. Yeah, thanks so much for having me. Really excited for this. Yeah. No, looking forward to the discussion.

You know, for those listening, you can't see Greg's background, but he's on brand with the Firefly Neuroscience background here on Zoom, but, uh, no, it's great. Uh, joking aside though, with, with that said, I recorded, like a, a super short bio of your background at the, at the outset of this episode, but let's, let's start there. If you can give us, like a, a two-minute kinda elevator style pitch of your, your journey leading up to taking on the CEO role at, at Firefly, that'd be great. Yeah, sure. Happy to talk about that. S- so my background is about 15 years, uh, in capital markets and also advising high growth companies.

And so, uh, it was about four years ago when I met Arun, who's got an incredible background, by the way, and he basically showed me Firefly as an investment opportunity. And so I came into the company, and I did some due diligence, and I was really blown away for a number of reasons. So, so one was the people involved. So Arun's had three med tech exits, one to IBM and one to Stryker. Hmm. Uh, the second was the incredible technology and the database that the company had. They've spent over 10 years and $60 million building the database and, and then getting that through the FDA.

And then when I looked around, uh, I saw a whole bunch of really exciting companies in this space backed by some of the smartest investors, uh, kinda household names, but none of them seemed to have the, the database and the FDA clearances that Firefly did. And so I invested in the company, uh, about four years ago. I took on a role as a board member, and I was pretty critical in terms of helping the company, uh, raise the capital and, and meet investors. And, and through those four years, I really understood the business and got to know the team a bit better and decided, uh, in January to step in as CEO.

I just thought the opportunity was so big and exciting, and I was really looking forward to it. Yeah. So about, about, about six months into this role, but, but almost more... sounds like more like f- five years kind of with pretty- Mm-hmm... pretty intimate knowledge of, of kind of the, the company. So with that said, I'm looking at the website ri- right now, which is Firefly Neuro. So we'll link to it in the full write-up on MedSider, but it's Firefly, just like it sounds, and then neuro, N-E-U-R-O, fireflyneuro.com. Give us a sense for kind of like, at le- at least at a high level, I mean, if you wanna drill into the, into the weeds a little bit, but at least at a high level, if I'm a, a freshman or sophomore in high school and I have no idea what, what you're doing, like, help me explain kind of what the technology does and, and the, the major, the major problem that you're, you're trying to solve.

Yeah. Happy to. So, so there's two pillars to our business. Um, so, so one is clinics and the second is pharma. So on the clinic side, what we do is we do objective measurements of the brain, uh, for cognitive disorders. So right now, why that's important is currently mental health is treated, it's very subjective. It's, "How are you feeling today?" And what happens is someone comes up to the doctor, says, "This is what I'm, how I'm feeling," and the doctor will say, "Hey, try this medication.

Come back and let us know, uh, how you're feeling, and if it works [audio glitches] with you, we'll stay on path, and if it doesn't, we'll try something else." It's, it's trial and error. Now, with our technology, you can scan the brain, you can objectively measure and see if it's, you know, if the treatment path is working or not, and people can come back for subsequent visits and, and track that. And so the business model there is, is a subscription model with a per-use fee. But, but why we like that model is because each incremental scan that we do, we get more data.

And as that database grows and grows, it gets richer and we get more insights, which we can then mine for biomarkers, but then we can also feed it into the other pillar, which is pharma. And so we view ourselves as, as a platform company in pharma, the, the picks and shovels, so to speak. And so we're agnostic to the type of company or the drug that they're developing, what we really do is we help them get that data and that insights to help them get through that clinical study. That's super helpful.

Yeah. And, and I could, I could see where you're going with the kind of that flywheel effect, right? The more scans you do, the database gets more richer, it gets more deeper, it gets more broader, right? And it, it turns into a kind of a, what, seeming like, seemingly like a, you know, a, a flywheel that doesn't stop spinning or a snowball, right, that kind of gets bigger as it rolls downhill, so. But on the, on the pharma side, just to, just to be clear, pharma companies are then coming to Firefly and saying, "We need... We'd like to access the database or access kind of biomarker in- information," what have you, right? And you're kind of, like, assisting them in their clinical efforts, their R&D efforts, et cetera.

Is that kind of like a- Yeah. What's exciting is, um, we actually haven't had any business development in pharma. They've actually all come knocking on our door. And so we've worked with Data, Novartis, Brightmind Biosciences, and so we can help them with their clinical trials in, in many different ways. A, a key piece is patient stratification. And so the example there at a high level is, say, you have 100 people go through a, a clinical study and they all, you know, the response rate is 30%. Well, that might not be strong enough to move to the next phase. Mm.

But what we can do is say, "Hey, we've noticed that a third of the population has mild depression, a third of it has moderate, and a third has severe based on the signals in their brain." And then we say, "Hey, we've noticed, you know, the, those with mild depression actually respond at 90%." And so now they can be much more focused and, and understand that patient population better to move on to the next, uh, phase in the clinical study. Got it. That makes, that makes sense. And I, I li- I like these plays because I, I think most, generally speaking, most med tech founders, they're like, "I, I'm, I'm working on this technology and this is the clin reg pathway and it's gonna be five, seven, 10 years, you know, before I ever earn revenue for the company."

And not that that's not typical or that's a pretty normal path, right? But in some cases there's, there's, like, alternative ways to drive revenue, right? I've had a, a few, a few, you know, CEOs on the program that have kind of, that have done maybe somewhat similar things, right? Where they, they have... there's a, there's a, there's an easier path to get to, you know, 510[k] clearance as an example, right? And may- maybe that's not their end goal, but it's an easier path to, like, effectively have a device that you can make claims around. But they, they find a way to drive revenue by partnering with, you know, CROs or other types of companies that want access to the data that that device is collecting. So it's a... I don't know. I guess I, I...

it's a cool point to emphasize because oftentimes there's, like, there's, there's unique ways to, like, you know, keep a company sort of, you know, capitalized, driving revenue, right? Even though maybe these interim steps aren't, are your, are its ultimate, ultimate goal. So it's kinda, it's kinda cool to, cool to see. So from a, from a lifestyle perspective, I know, I know Firefly's, is kinda unique in the fact that you're, you're publicly traded, right? Under the, the ticker AIFF, which is, which is, which is pretty cool. But when did you go public, and kind of are you, are you just focused on the, the US right now, or do you have a kind of a global, global commercial kind of, you know, play as it, as it relates to the brain, the brain scan aspect of the, of the technology?

Yeah. So we went public through a reverse merger in August of last year, so w- we haven't even been publicly traded for a year yet. But that was really to, to go public and get more visibility into c- you know, to investors and enhance our, our profile. And for now we're really focused on executing in the clinics in the US. We do have a number of pharma partnerships globally, but from a commercial perspective, you know, we're trying to stay incredibly focused and try to just win in, in core markets.

And so for now it's just kind of heads down focusing i- in the US. Cool. Awesome. And again, fireflyneuro.com is the website. Definitely encourage you to, to, to check out the technology in more details. It's pretty cool. But we'll link to it in the full, the full write-up, but it's fireflyneuro.com, just as it, as it sounds. So, uh, with that said, um, Greg, I'd love to kind of dive into a few, few different kind of topical or kind of functional areas, uh, right? And, and, and get kind of your, you know, key lessons learned, things that you think other, you know, would be valuable, you know, for other, other med tech CEOs to kind of really, really, really...

Lessons that, that you think would be valuable for them to take home. And, and the first one is really around capital markets, right? I mean, you, you just mentioned you spent the previous, what, like 15 years in the capital markets, and that ultimately led to you, you wanting to kind of get more operationally involved and take on the CEO role at, at, at Firefly. But when you think about your experiences, either raising money for, for Firefly or just other friends, right, that you know in the space that, that have struggled kind of keeping their companies capitalized, this is just might be one of the hardest things to do, right, as an early-stage med tech company. So what, what... how do you typically advise them? What do you, what do you see, whether you want to kind of approach that from mistakes that you typically see, or just kind of these are the one or two things that, you know, CEOs need to really, you know, get, get right, uh, when it comes to this, this area?

Yeah. It's, it's, it's a great question. [laughs] And so, you know, the number one reason, uh, that companies fail or startups fail, I think, is they just run out of capital and, and, and a runway to actually go and execute to get cash flow positive. And so, you know, it's a, it's a critical piece to any of these businesses, um, these pre-revenue companies. And so for us, it's not even... it's not just the amount of capital that you raise, but it's also who your investors are and, and the terms that you raise them on.

And so I, I see a lot of companies struggle in this aspect, where they might not have the right investors long term, that as the company keeps growing and maturing, they may not be there to support that next level of growth. And then the founder's constantly out there spending all their time raising capital and not actually on, on the underlying business. And so, you know, I think it's who you raise that money from as well, and that also dictates, you know, the terms, uh, that you raise them.

So, you know, my, my advice is really try and find the right long-term partners that can help you strategically, uh, and build your business and, and not get too stuck on valuation and the amount of capital. It's, it's really who y- who you're working with long term is what I think is really important. This is an area that, you know, someone listening that's like, "I'm desperate for capital," right? They've been banging on doors for, you know, six months, nine months, a year, and they're, you know, they're, they're trying to, trying to make sense of the lack of traction.

You know, they may say, they may counter that and say, "Well, that's, that's easy for you to say, Greg. You've got all this, you know, th- these connections, and you've got all this experience in capital raising." But I think, I think from my perspective, it's such a crucial point because if you end up... let's say you, you end up saying yes to a certain investor, right? You got... you, you know, you're able to find, you know, some people that'll inject capital into the company, and maybe that buys you a year or 18 months, whatever. But if, if they're the wrong investors, right, that year or that 18 months, not only could it be brutal, right, but it... you could o- you could oftentimes be in a much worse scenario, you know, when you, when you fast-forward a year or two down the road.

So that seemingly, like, quick yes could end up being, you know, causing a lot of turmoil. So I think it's a really, really great point around, like, who you're, [laughs] who you're, who you're raising from is, is quite, quite crucial. Well, I want to make a point, 'cause y- you mentioned some of these companies, you may be not in a position of strength, and you really just have to go and r- whatever. You'll take whatever capital you can get. You know, for us, it wasn't always an easy... it was a long, bumpy journey to get to where we are, and one of the biggest things that I learnt through this whole process in, in healthcare is y- you need a strong team that is multidisciplinary.

So y- you need a strong medical officer. You need a strong technology person. You need a strong regulatory person. So you can't do everything yourself. And so if capital raising is your weakness because, you know, you're founder led and you're a physician and you really understand the science, then I would say go partner with someone who has that strength, 'cause they can help, help speed that along, and it can be very complementary. I think if you try to do everything, I think there's just... healthcare is just way too complicated that, that, that's really challenging. Oh, yeah.

So I think it's, it's have the right team and, and find those people that can help you with the capital side. Yeah. So, so crucial, 'cause there's, there's a lot of... I've ha- I haven't had a lot of, like, physicians per se on the program, but I, I, I interact with a lot of physicians that have an idea maybe, or they're already, like, actually they've made good progress on their concept. Maybe they're in, into pre-clinical, as an example. But they, they've got a, a full-time gig, right? Like, they're still, like, practicing medicine, and sometimes it's just hard to let go. It's hard to let go of their baby, to hand it off to someone that can, you know, step in and operationally run the company. But, uh, I totally agree. Like, if you...

you've got to be thinking about this as, like, you know, from a sustainable perspective. You're gonna have to have, like, these, these key spokes, right? These key cogs. Mm-hmm. You know, whether it's, whether it's R&D, whether it's, you know, reg clin, whether it's, you know, kind of capital raising or finance, if you will. So, so yeah, I think that's a [laughs] ultimately you're gonna have to make that call, right? You can't, you can't, you know, sort of have two, two full, two full-time gigs at the, at the same time and expect one to, to do well. And capital raising is a full-time job. [laughs] Yeah. [laughs] At least in my... So, so I'd encourage people to, to make sure you have a great team, and find those people that can help you. That's good stuff.

Let, let's, let's move on to kind of this, this platform kind of technology. You, you mentioned it earlier, and I know i- based on kind of our notes that you recently identified a new, a new cognitive brain age biomarker, which I think you announced in a, in a, in a press release, and you've got, you know, other, you know, dementia clinical trials, I think, that are either ongoing or maybe that you've completed. And so a- anyway, I guess where I'm going with this, this question is you've got probably a lot of different areas, right, that you could go and, and, and look at. When you're dealing with sort of this underlying kind of platform technology, how, how, how do you prioritize? How are you kind of thinking about, like, where to, where, where to focus?

[laughs] It's a great question, and I think, um, the exciting part about Firefly And maybe the weakness as well is that we have such a big opportunity. We know so little about the brain and, and mental disorders, and our database covers, I think, over, over a dozen different cognitive disorders, so concussions, depression, dementia, ADHD, Alzheimer's. So there's so many paths that we can take this, from a disease state, from a clinician state, and then from a pharma.

And so for us, we're hyper-focused on this year just executing in neurology, and our focus for the most part is, is dementia. You know, we have this big baby boomer generation that, that's aging and an aging population. You know, I think one of the key things that they care about is, is their brain. So for us, you know, we wanna focus there, but as we keep, you know, building out our network of clinicians and keep getting more data, you know, we want the market to kind of pull us and tell us, "Hey, by the way, you know, here's, here's all these exciting ways to grow," and we can e-evaluate them to say, "Okay, look, there's 20 different directions we could take it, but which one's gonna get us the best return on investment or ROI in the short term and the long term?"

Because we can't stretch ourselves too thin. We have to focus. And so if we execute and do really well on our first initiative, then the market will enable us to keep growing, giving us the privilege to then work on the second, the third, and the fourth. And so for us, I think that's, that's... You know, there's so many exciting opportunities, but it's try [chuckles] it's just trying to make sure we just do one at a time. And it's a good challenge to have, right? To have, like, so many opportunities that you could potentially pursue. But that, that framework of, like, nailing one and then letting the market, like, signal, like, looking for those signals and letting the market kind of pull you maybe in the, in the, in the next direction once you've been able to showcase that you can execute in, in, in one area.

It's, like, such a healthy, I think, framework 'cause again, I think there's a lot of people that are, that are, that'll listen to this and be like, "I'm, I'm, I'm stuck in this scenario where it's like, it's hard to choose," right? Like, where it feels like we're doing pretty well in one area, but like, you know, there's, there's other opportunities, and there may be opportunity costs if we don't pursue them now. But it's like, you know, I think that, that idea of let's nail one, and then, and then let the market pull us into other areas if, if the opportunity is there. [upbeat music] Hey, everyone. Let's take a quick break to talk about Fast Wave Medical, the company I co-founded and lead as CEO.

We're developing next-generation intravascular lithotripsy systems, or IVL for short, to tackle complex calcific disease. The IVL market is valued at over $10 billion, but there's currently only one major player. In early 2023, we opened up an investment opportunity to our community, and within a month we secured close to $10 million. Then in early '24, we closed an oversubscribed $19 million round in just a few weeks, bringing the total investment into Fast Wave to over $40 million. Corporate interest in the IVL space is growing, too. The $900 million acquisition of Bolt Medical by Boston Scientific and then J&J's $13 billion acquisition of Shockwave Medical signals a lot of attention towards emerging IVL startups like Fast Wave, and we're making some serious progress.

Fast Wave recently received its seventh patent for our differentiated laser IVL platform for coronary applications. On the clinical side, last year we completed the first in-human study of our advanced electric IVL system with some pretty compelling results. Next up in 2025, we have IDE trials planned for both our peripheral and coronary IVL platforms. So if you're interested in investing in the fast-growing IVL market, sign up for our investor waitlist at fastwavemedical.com/invest. Again, that's fastwavemedical.com/invest. Now let's get back to the conversation.

[upbeat music] I want to talk a little bit about the, the NVIDIA Connect program too because I don't-- I think you might be the first CEO on MedSider that's been a part of, of this, of this program, and I, I don't, I don't... To be honest, I don't really know much about it. So maybe if you can start kind of like, tell us a little bit more about the Connect program. I think everyone that's listening is probably familiar with NVI- [chuckles] NVIDIA at this point. Maybe, hopefully you maybe got in earlier, uh, early in, in [chuckles] NVIDIA before their boom. But, uh, tell us a little bit more about the Connect program and then, you know, how you're, you know, how, how you're using it or how it's advantageous for, for Firefly. Yeah, definitely.

Um, no, it was a really exciting, um, program that we got accepted into. And so, you know, NVIDIA has this rigorous process on who they kind of partner with and who they let in, and so we applied to their Connect program and were fortunate enough to get accepted. And, and they really partner with innovative, cutting-edge technologies. And so we believe we're, we're one of the leaders in trying to understand the brain and, and the database on cognition. And so for us, I think it, it, it made sense for both parties. Where we're going with this over time is, I think the most valuable asset that Firefly's gonna have, uh, over time is the database.

And so what you've seen with ChatGPT and these large language models, i-ideally we wanna build something on the brain. Mm-hmm. And so as we kind of keep building and building this database of all these, these EEG scans, you know, it's like as you can start pulling in other data, like maybe it's cardiac EKGs or some, some blood data or tying this with EMRs, you know, we don't, we don't know yet what we're capable of doing and learning- Mm... and what we're gonna discover along this process.

And so for us, I think that's the exciting part is as we get more data, we're gonna just learn so much more about the brain and start to say, "Hey, we've, we've seen this brain so many times. We know what their dementia's gonna look like in six months, 12 months, three or five years," or, "We've seen this brain so many times. We know that this treatment path will or will not work for them." Mm. And so, you know, everyone's got a unique brain that's totally different or, you know, totally different biology. And so to be able to give patients specific treatments, I think, is, is where one day this, this can eventually end up.

I'm sure you probably thought about this too, but, like, I, I could see a, a scenario where with the right database, like, this could become, you know, super compelling from a consumer perspective too, right? Where the, the previous company I started before, Fastwave, um, we saw... I can't remember the name of the company. They didn't build the technology, but they largely partnered with, with professional athletes and, and, and their trainers because there was, like, especially in the PGA Tour it seemed like there was, like, high interest in, in, like, you know, active monitoring of, of brain in a, in a, in a pretty tech- in a, like, brain capacitor cognition in a pretty technical way. And anyway, long story short, I could see that, I could see that becoming even that much more interesting, right, if it was more accessible from a, kind of a, a consumer, a consumer perspective.

Well, it's interesting that you mention that 'cause, yeah, you've seen this whole wave of, of consumer products, right? Yeah. Like Apple Watches and Whoop and whatnot. Through the Evoke acquisition, we actually do have a consumer product. Mm. And so it's a really interesting app, and, uh, and it's tied to a, a h- a headset, and you actually play the games in the app, uh, without a remote control but with your brain. Oh, interesting. Huh. It's meant to help you, you know... The analogy is it's like a gym for your brain. Like, if- Hmm... if you need to learn how to, like, de-stress or to focus.

And so, you know, we have a really unique asset there, uh, that we're still trying to strategize to figure out, you know, how best to monetize it. And, and this kind of goes back to the kind [laughs] the topic on focus is, like, so we have a lot of really exciting things. We're trying to figure out, you know, what the sequence of, of that looks like and that rollout. But it, but it's a really interesting technology. I'm getting you distracted with c- with the consumer, the consumer [laughs] the consumer plays. [laughs] But, but, but, like, uh, kind of... I mean, we're laughing about it, but, like, you've seen some of these. Is it Superhuman? And there's another one, I think, is it Function? I can't remember. But they, like, they've recently raised, gosh, a monster valuations, and in essence they're, they're basically, like, providing blood tests in an easy-to-use, you know, kind of platform for people to kind of, like, just monitor their health in a more granular way.

And, like, that, that kind of stuff is just only gonna g- continue from my perspective, right? So if there was, like, a, a way to better understand kind of how this protocol, you know, what- whatever you're on, right? Whether it's, you know, whether you wore an Oura or a Whoop device and you're mon- you know, you're pretty rigorous about monitoring sleep, like, how that actually parlays into, like, actual brain, brain health in a, in a more quantitative way, I mean, I think that'd be, could be, could be k- kind of cool. If you can start tracking your brain on a daily basis and start seeing patterns and, and being able to help correct and improve your, your brain health, I think that's massive. So- Yeah...

it, it's a pretty exciting opportunity. Yeah. Yeah, no doubt. You mentioned the, the Evoke acquisition, right? Yeah. So, so I can't rem- I don't, I don't have it in front of me, like, when, when you actually made that, made that deal. Sure. But yeah. Can you, can you touch on that? Like, what, what was... Yeah, tell us a little bit more about Evoke and why you, at, at this stage, why you decided to kind of pull the trigger on, on that deal. Yeah. Uh, so we, we acquired Evoke just under two months ago, and, and we're really excited and thrilled about it. So the backstory here is Firefly did an excellent job building the database and the algorithms and really understanding the brain.

What Evoke did w- is they did an excellent job building a network into all these clinicians in the US. And, and they have a really strong team of industry experts or EEG experts, um, specifically for clinicians. And so through that huge distribution network, they ended up building a database quite significant. I think it was around 100,000 scans. And so for us, you know, you sort of had two of the biggest ERP databases out there, and con- combining them, for lack of a better word or for the pun, is it was a complete no-brainer.

[laughs] And so, you know, we're really excited and, and I think it also added a couple interesting pieces. Um, you know, their founder, you know, his story is he was treating veterans with PTSD and looking for better treatments, and so he built this, this system and really has been able to help patients and clinicians for, for over 10 years, and he just comes to the team with such insight. I mean, he's been reading these EEG reports for, I don't know, maybe 15-plus years. And so the insights that he understands and can get i- is really fascinating.

And so for us it's also, you know, it's a database, but then also working with individuals like that can... who can help us, you know, guide the science is really exciting. Yeah. It reminds me of how, like, complicated, like, the, the brain is. It's, like, amazingly complicated. My, my mom was diagnosed with dementia and, uh, and, and Lewy body Alzheimer's, like, gosh, it's a year and a half ago now, right? And, and kind of go- going through that personally and trying to figure it out, right, was like, I mean, I'm, I'm in this space, and it's like, that's hard enough. I can't imagine, you know, if you've never, like, operated really into any, any, in a degree in the healthcare environment, like, how, how difficult that really is.

And, and, and one of the things that kind of st- stood out to me kind of like as we kind of navigated that as a, as a, as a family is, like, these neuroscientists and neurologists, like, they have no capacity, right? It's like trying to get, you know, trying to get an appointment with a specialist is like pulling, you know, pulling teeth. You know what I mean? And, um, my parents live in, uh, live, live in central Iowa, and so it's not like New York City or something like that where you, you'd maybe expect a little bit more, a little bit more difficulty there. And so, so yeah, I mean, I... With more accessible technology to just maybe help, help understand sort of this stuff, you know, I, I, I think that's, uh... I mean, there's tons of opportunity there. Yeah.

Well, well, actually, um, my president joined full time a couple months ago, and, uh, he had a similar story where I think it took two years for them to diagnose, uh, one of his parents, uh, with Alzheimer's. And so we're looking at this and, like, there has to be a better way. Yeah. And neurologists are, are full. I mean, I think there's, like, 6 or 12 month waiting lists to s- Yeah... to see neurologists in certain areas. And so we're not gonna overnight 10X the number of neurologists in the country. But what we can do is provide tools for them to, to increase their efficiency and democratize access to these tools to the masses.

And so- For us, it's getting in the hands of, of neurologists and industry leaders, um, and then hopefully over time building this into primary care in the masses. So, so it's, it's, it's helping people with dementia, um, and Alzheimer's, but then, you know, also, you know, that concussion, that depression, that anxiety- Yeah... all these things that, you know, people struggle with on a day-to-day basis. Yeah, no doubt. Let's kind of stick, stick there for a little, uh, a little bit, right? You're, you're, you're actively commercializing this technology now. Again, kind of tons of opportunity, right? Do you, you know, partner with, you know, health systems? Do you, like...

Do you try to partner with, with pharmacies, right, to get this into, like, more, you know, more, um, a d- different sort of point of care, um, as an example? Probably a lot of different avenues you, you've considered. Talk to us a little bit more about your, your approach to kind of commercializing this at the, at the, the stage where, where Firefly is at now. Yeah. So we have a quite a, quite a vast distribution network now, uh- Mm-hmm... across the US. We're in over 60 active clinics. And so our commercialization plan- Mm-hmm... is now just focused on sales and marketing. So how do we grow that, you know, as fast as, and sustainably as we can?

And part of that process is reaching out and educating the market and, and finding new accounts, but then also working with our existing accounts to say, you know, "What do you like about the, the way the report or the technology is? Uh, where do you see the most value? Where we can we improve?" And really working that with that core customer base to say, "Hey, if we added one more feature to the report or one more insight, what would that look like and how excited would you get?" So we can use that to then get into much more accounts. We also focus on the science as well. So wh- when you're dealing in, in healthcare, a lot of people say, "Okay, this is... Sounds great.

Like, show me the data and show me the proof." Mm-hmm. And so for us, it's making sure our science team is focused on, on research and publications- Mm-hmm... for that specific use case. And so it's, it's constantly listening to our customers to say, "Hey, you know, here's some really exciting stuff that I'm doing with my patients." And then we can work with them on publishing a, a, a report to then use that to, to sort of get more traction. So I think it's sort of that snowball effect, right? Like we're in the market, we have a deep and decent customer base, and it's all about just kind of building off of that. Are you primarily...

So it's like the, the clinics that you, that you're in so far and that you, you, you know, hope, hope to be in over the next, you know, several years. Are you primarily utilizing like direct, direct sales folks or distributors or like what, what's your approach there? Yeah. We, we have a, a direct sales team, and I think for a company of our size, I think that's critical because it really allows you to build that relationship with your customers. And then as we get bigger, we'll see how that evolves. But, but right now it's, uh, yeah, it's a great internal team of, of sales reps. Got it. Got it.

I know we don't have a ton of time left, but I, I wanna ask you a little bit more about the, the reverse merger, right? 'Cause the fact that you're, you know, dur- Firefly's publicly traded, right? That's a... You know, I don't, I don't have a lot of CEOs on, on the program that are, that are operating in a, in sort of, uh, in, in the public domain like, like you are. So for others that other, uh, you know, CEOs that are listening to this or maybe considering their paths forward from a capitalization perspective, maybe they're looking at a, a Series C or a Series D, but they're also maybe considering an IPO or, you know, getting into the public markets, what are, what are a couple like big lessons learned, right, that ei- either, either directly from your experience at Firefly or even just your, your prior, you know, your prior experience kind of operating in the, in the capital markets?

How much time do you, do you have? [laughs] Right. This is like an- another hour, hour-long conversation probably. [laughs] Yeah, exactly. Boil, boil it down. Sim- simplify it for us, right? For the, for those that, that haven't, uh, don't have the, the swings at the plate that, that you've had, that you have. I think for us, we took a very untraditional path. One is going public as early as we did, and, and the second, going public through a reverse merger, um, which adds a little bit more complexity. For us, when you're raising capital, it was, it was trying to map out, um, a path that made sense for the company based on where it was.

And so when we started speaking to some of, you know, to VCs and some of the biggest VCs out there, what we encountered was it was, it was a cookie cutter approach. Um, it was, it had to be, you know, three years from founding the company. When was the last raise? How quickly? Like you needed to be on a, on a specific path, and if you didn't perfectly fit this criteria, then they weren't interested, which to us was interesting 'cause they weren't really looking at us at the merits of the company, but more so the, the structure of the company's involvement.

And so when we looked at it, the markets were pretty shaky, and the IPO market wasn't, wasn't that strong. And so you, you know, the IPO went... You know, you usually get all your docs, and then it's like, "You're going public this week. Hopefully, the market's strong that week or not." And for us, that was just too big of a risk. And so for us, we went public through the reverse merger because it was, it gave us the, the cleanest path and, and the most accuracy of knowing and predictability of, of knowing we'll go public at a certain date.

And so there's a lot of advantages and disadvantages, um, of being a publicly traded company. But I would say the advantage i- is you have access to different pools of capital. And so for us, we've been fortunate enough that we have an exciting story, and we keep executing, and we keep doing exciting things. And so when we disseminate news, you know, people hear about it. And, and so it helps also, you know, just marketing other clinics. Other people are finding out about us that they wouldn't have otherwise had. But also because of the liquidity in the stock, you know, it enables investors to say, you know what, if, you know, I'll come in because I know that I'm not gonna be in this investment for potentially 15 years with no exit.

I, you know, I can watch this company grow. And, and then also they can see our financials. Everything's public, so there's a little bit more trust investing in the company because there's, you know, a history of us for, you know, being in a regulated environment with the SEC and Nasdaq. Those are really interesting thoughts, all, all very good. And I, I think, I mean, this is just a, a hunch, but as the, the, the gap or the hole kind of gets bigger for, I would say, kind of seed Series A, Series B kind of med tech companies, right, that are, are still maybe in, in some pretty extensive clinical work.

They're still pretty far away from c- from, from revenue. Oftentimes, they're-- they have to kind of advance to the next stage, right, through a non-cookie cutter approach, right? So they don't, they don't fit that cla- that classic kind of profile that the most VCs are looking, looking, looking for, and I think you're d- I mean, that's certainly been my experience. I mean, if you, if you, if you veer t- you know, too far off that pathway, you know, you could be building a really phenomenal company, you'd be re- in a, in a really promising category, and if it just... if it doesn't fit, you know, those puzzle pieces don't, don't fit together, right, you just don't get the s- the serious looks, right, that you otherwise, uh, otherwise would have. So I guess where I'm, where I-- where my, my head goes is that I think this, this gap is gonna widen, and the companies that do make it through sort of that dip, if you will, or the, the dearth of that, that life cycle and make it, make it on the other side, they're gonna be in a, in a scenario where, because they haven't followed that cookie cutter approach, they're gonna have to get creative, right, around how they, how they continue to capitalize the company.

And so it sounds like, you know, I, I don't know. I mean, maybe not Firefly's the, the perfect example, but you were kind of faced with the same, same question, right? Like, if we're gonna, you know, continue to kind of move, move forward, we don't have that, maybe that classic profile, right, that, you know- Yeah... growth stage VCs are looking for, and we gotta, we gotta look at this a little bit, little bit differently. Yeah, and it gave us- Yeah... other advantages. I mean, we're able to do acquisitions, uh, with also stock, which, you know- Yeah... you're private companies and someone's looking for an exit event, it's, it's much easier selling to a publicly traded company than a, than a private company.

And so th- there's tons of advantages of being public that's been really helpful to us. And I guess that, to your point is, you know, like, if you're building an early stage company, there's no right answer. I mean, there's just so much different avenues you can explore. Um, and this was- Yeah... one of them that we took. Yeah. That's cool. I mean, I know we, we didn't ha- we don't have a ton of time to kind of go, go deeper on this topic. I w- I wish we did, right? [laughs] 'Cause there could be probably some- Yeah... some more that we could, we could, we could tease back. But, um, with that said, I'm looking at the clock, and I wanna be sensitive to your, your schedule. So, so let's get to the, the rapid fire portion of this, this interview. But again, for everyone listening, fireflyneuro.com is the website. We'll link to it in the full writeup on MedSider.

If you're new to this, this program, haven't ever listened to an episode, we, we do these long- longer form articles that accompany the podcast that serve as a way to kind of read through basically a summary of a lot of the, the key lessons, key learnings that, uh, that our guests, our guests, uh, share. So we'll link to the, to Firefly in that writeup as well. So highly encourage everyone to either check out the long form article or just, uh, just hop on, hop on over to, to Fl- fireflyneuro.com. So with that said, um, questions are rapid fire in nature. Uh, uh, Greg, if you wanna expand a little bit, that's, that's, that's perfectly fine. But we're recording this in, in late Q2 of '25. But fast-forward a year.

Take us to mid, mid '26. What are you most excited about over the next 12 months? I'm excited about the growth trajectory that we're on. Um, every day, you know, I see the progress of the team, and so, you know, what I hope to see in a year's time is, you know, significantly more clinical sites, you know, more publications, um, more customers, and a bigger team. So it's just, for us, it's all about just kinda sales, marketing, and growth, which is, which is the fun part. [laughs] No doubt, no doubt. Um, take us back to maybe your, your favorite restaurant in Canada, and maybe we just wrapped up a, an intimate dinner with a bunch of other, you know, med tech, you know, founders or CEOs.

If there's one lesson that you really want to leave them with, right, that are gonna best position their, their, their ventures for success, what would that be? To me, it's all about the team and making sure you have the right people on your team. And so for me, I'm fortunate enough that I get to work with a whole bunch of really, really talented and smart individuals. But I do wanna bring up, uh, my president, Dave DeCaprio, who's done an excellent job, and his whole side is he's an MIT alumni and spent his career in, in healthcare and helped map the Human Genome Project.

But CMS had a AI healthcare competition, and all the who's who were there. I think there was like three or 400 companies. It was like IBM Watson, Mayo Clinic. All, all the big names were there, and Dave's small little team ended up winning the competition. Uh, and he's ranked, I mean, the number one guy in sort of healthcare AI. And so the point here is, like, have a strong team. You can't do everything in this industry. So for me, like, I can help capital markets side, but, but he's done an excellent job in sort of the software and the technology and the operations. And, and that's the number two.

As, as we keep going down, I mean, there's our CTO, our head of science, I mean, all these guys. So to round it all off, it's, it's the team because you, you need, you need a strong team that can execute. Yeah. It sounds, sounds cliché, but so, so important. I mean, like, literally just using the car as an example, you have one, one wheel that's kinda off a little bit, you know, and it impacts the rest of the... I mean, it impacts your drive, you know, uh, to, to a large degree. So, um, yeah. I, I'm right there, right there with you. Um, all right, last question. Take us back to kind of like la- late, late 20s or, like, that general kind of, you know, timeframe. Anything that you'd whisper in the ears of the younger, younger Greg at that point in time?

You, you know, I think the, the two... There's a few learning lessons for me. Um, I think perseverance is, is one. If you're trying to do something, you know, big and breakthrough i- in your career, it, it's gonna take time. There's gonna be highs and lows. So I would say to people, "Don't, don't chase the, uh, the short-term monetary incentive," like, "Hey, this job can pay me this." Find an opportunity that you think is exciting and that you can learn from because it's gonna take time. There's gonna be highs and lows, and you gotta be passionate about it 'cause that's what drives you. No doubt.

Es- especially, especially in a highly regulated environment like healthcare, and we were, we were kind of joking around before we hit the record button, but, you know, you've got the, the double whammy, right? In that you've gotta stay within the, the guardrails of FDA, but also stay in the, within the, the guardrails of, uh, of, of the SEC as well now as a publicly traded company. But, uh, but no, this is, uh, I couldn't, I couldn't agree more. That's good, good words of wisdom to kind of end the, end the conversation with. But, um, again, everyone, fireflyneuro.com is the website, just as it sounds, firefly, uh, neuro.com. We'll link to that in the full writeup on, on MedSider.

But again, Greg, thanks for carving out a little bit of time to hop on, uh, MedSider Radio. Appreciate it. Yeah. Really appreciate the time. Thanks so much. Yeah. And I'll have you stay on the line. But for everyone listening, you made it this far. Thanks as always for your, uh, for your listening attention. Until the next episode of MedSider goes live, everyone, uh, take care. [upbeat music] Hey, it's Scott again. One quick thing before you go. You see, I love bringing you insightful conversations with the best founders and CEOs of medical device and health technology startups. But here's the thing, I'd be super grateful if you could help me reach even more ambitious doers who share our passion. So if you found value in this podcast, if you found yourself nodding your head while listening, or if you simply enjoy what we're doing with MedSider, please take a moment to leave us a review. It's super easy.

Just open your Apple Podcasts app or the podcasts app of your choice, search for our show, and scroll down to the ratings and review section. Leave your honest thoughts and hit that five-star rating if you think we're worthy. Your feedback is incredibly important, and it's the best way to ensure we keep bringing you awesome discussions with leading founders and CEOs. So take a moment to be a good friend and leave that review today. As always, thanks for being a part of our journey and for helping MedSider continue to grow and evolve. Your support is greatly appreciated. All right, enough talk about reviews. Stay tuned for another informative episode coming at you soon. [upbeat music]

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. How to Build Trust in a New Category: Interview with Wizard Wellness CEO Lorne Lucree

    Nov 16, 202650 minAudio

    In this episode of SNL, we sat down with (https://www.linkedin.com/in/lorne-lucree-mba-3585942/)Lorne Lucree (https://www.linkedin.com/in/lorne-lucree-mba-3585942/), the founder and CEO of...

    Credit the people on this episode

  2. What P&G and Amazon Taught this Medtech CEO: Interview with Panther Life Sciences CEO Marcus Mounir Hanana

    Nov 9, 202651 minAudio

    In this episode of SNL, we sat down with Marcus Mounir Hanana (https://www.linkedin.com/in/mmhanana/), CEO of (https://www.pantherls.com/)Panther Life Sciences (https://www.pantherls.com/). Panther is developing...

    Credit the people on this episode

  3. How to Build a First-of-Its-Kind Device by Proving the Riskiest Part First: Interview with Ammortal CEO Brian Le Gette

    Oct 26, 202653 minAudio

    In this episode of SNL, we sat down with (https://www.linkedin.com/in/brian-le-gette-8956252/)Brian Le Gette (https://www.linkedin.com/in/brian-le-gette-8956252/), co-founder and CEO of (https://ammortal.com/)Ammortal...

    Credit the people on this episode

  4. Why You Can't Boil the Ocean When Building a Device: Interview with Vital Signals CEO Tom Moss

    Oct 19, 20261 hr 4 minAudio

    In this episode of SNL, we sat down with (https://www.linkedin.com/in/tommoss/)Tom Moss (https://www.linkedin.com/in/tommoss/), co-founder and CEO of (https://signalring.com/)Vital Signals (https://signalring.com/),...

    Credit the people on this episode

  5. Finding Your Unfair Advantage Against Industry Goliaths: Interview with Happy Health CEO Dustin Freckleton

    Oct 12, 202651 minAudio

    In this episode of SNL, we sat down with Dr. Dustin Freckleton (https://www.linkedin.com/in/dustinfreckleton/), founder and CEO of (https://happysleep.com/)Happy Health (https://happysleep.com/). Happy Health delivers...

    Credit the people on this episode